Eliem Therapeutics

About:

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.

Website: http://www.eliemtx.com

Top Investors: RA Capital Management, LifeArc, Samsara BioCapital, Deep Track Capital, Janus Henderson Investors

Description:

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Total Funding Amount:

$291M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Redmond, Washington, United States

Founded Date:

2018-01-01

Contact Email:

media(AT)eliemtx.com

Founders:

Andrew Levin, David-Alexandre Gros, Valerie Morisset

Number of Employees:

11-50

Last Funding Date:

2024-04-11

IPO Status:

Public

Industries:

© 2025 bioDAO.ai